Condition: Cardiomyopathies · Heart Diseases · Cardiovascular Diseases · Sponsor: Rocket Pharmaceuticals Inc.
The goal of this study is to describe the natural history and clinical events for patients who have Arrhythmogenic Cardiomyopathy with Pathogenic Plakophilin-2 Variants (PKP2-ACM) managed with standard of care.
This description comes directly from the study's public registry record.
Clinical Information · 646-627-0033 · clinicaltrials@rocketpharma.com
Always discuss trial participation with your own doctor first.
| Boston Children's Hospital | Boston, Massachusetts, United States | Recruiting |
| Duke University | Durham, North Carolina, United States | Recruiting |
| Amsterdam UMC | Amsterdam, Netherlands | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06644742